Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 510

1.

Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report.

Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, Giaj-Levra M, Giaj-Levra N, Girard N, Greillier L, Lantuéjoul S, Edwards J, O'Brien M, Reck M, Smit EF, Van Schil P, Postmus PE, Ramella S, Lievens Y, Gaga M, Peled N, Scagliotti GV, Senan S, Paz-Ares L, Guckenberger M, McDonald F, Ekman S, Cufer T, Gietema H, Infante M, Dziadziuszko R, Peters S, Porta RR, Vansteenkiste J, Dooms C, de Ruysscher D, Besse B, Novello S.

J Thorac Oncol. 2019 Aug 6. pii: S1556-0864(19)30655-0. doi: 10.1016/j.jtho.2019.07.025. [Epub ahead of print]

PMID:
31398540
2.

Brain metastases: costs for care need to be spend more effectively!

Postmus PE.

Ann Palliat Med. 2019 Apr;8(2):207-209. doi: 10.21037/apm.2019.02.04. Epub 2019 Mar 1. No abstract available.

3.

Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapy.

Morgensztern D, Ko A, O'Brien M, Ong TJ, Waqar SN, Socinski MA, Postmus PE, Bhore R.

Cancer. 2019 Jul 15;125(14):2394-2399. doi: 10.1002/cncr.32114. Epub 2019 Apr 1.

PMID:
30933354
4.

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.

Cho BC, Obermannova R, Bearz A, McKeage M, Kim DW, Batra U, Borra G, Orlov S, Kim SW, Geater SL, Postmus PE, Laurie SA, Park K, Yang CT, Ardizzoni A, Bettini AC, de Castro G Jr, Kiertsman F, Chen Z, Lau YY, Viraswami-Appanna K, Passos VQ, Dziadziuszko R.

J Thorac Oncol. 2019 Jul;14(7):1255-1265. doi: 10.1016/j.jtho.2019.03.002. Epub 2019 Mar 7.

5.

Renal imaging in 199 Dutch patients with Birt-Hogg-Dubé syndrome: Screening compliance and outcome.

Johannesma PC, van de Beek I, van der Wel TJWT, Reinhard R, Rozendaal L, Starink TM, van Waesberghe JHTM, Horenblas S, Gille HJJP, Jonker MA, Meijers-Heijboer HEJ, Postmus PE, Houweling AC, van Moorselaar JRA.

PLoS One. 2019 Mar 7;14(3):e0212952. doi: 10.1371/journal.pone.0212952. eCollection 2019.

6.

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).

Morgensztern D, Cobo M, Ponce Aix S, Postmus PE, Lewanski CR, Bennouna J, Fischer JR, Juan-Vidal O, Stewart DJ, Fasola G, Ardizzoni A, Bhore R, Wolfsteiner M, Talbot DC, Jin Ong T, Govindan R, On Behalf Of The Abound L Investigators.

Cancer. 2018 Dec 15;124(24):4667-4675. doi: 10.1002/cncr.31779. Epub 2018 Nov 1.

PMID:
30383906
7.

Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study.

Reck M, Mellemgaard A, Novello S, Postmus PE, Gaschler-Markefski B, Kaiser R, Buchner H.

Onco Targets Ther. 2018 Aug 6;11:4573-4582. doi: 10.2147/OTT.S170722. eCollection 2018.

8.

Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice.

Califano R, Lal R, Lewanski C, Nicolson MC, Ottensmeier CH, Popat S, Hodgson M, Postmus PE.

Future Oncol. 2018 Oct;14(23):2415-2431. doi: 10.2217/fon-2018-0330. Epub 2018 Jul 6.

9.

nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial.

Gridelli C, Chen T, Ko A, O'Brien ME, Ong TJ, Socinski MA, Postmus PE.

Drug Des Devel Ther. 2018 May 24;12:1445-1451. doi: 10.2147/DDDT.S155750. eCollection 2018.

10.

Prophylactic cranial irradiation for stage IV small cell lung cancer, live longer or reduce morbidity of brain metastases?

Postmus PE, Smit EF.

J Thorac Dis. 2017 Oct;9(10):3572-3575. doi: 10.21037/jtd.2017.09.50. No abstract available.

11.

Changing health care costs for NSCLC, what does it mean?

Postmus PE.

Lung Cancer. 2018 Mar;117:62-63. doi: 10.1016/j.lungcan.2017.11.006. Epub 2017 Nov 11. No abstract available.

PMID:
29174372
12.

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S; ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21. doi: 10.1093/annonc/mdx222. No abstract available.

PMID:
28881918
13.

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, Han B, Ganea DE, Von Pawel J, Vladimirov V, Fadeeva N, Lee KH, Kurata T, Zhang L, Tamura T, Postmus PE, Jassem J, O'Byrne K, Kopit J, Li M, Tschaika M, Reck M.

J Clin Oncol. 2017 Oct 20;35(30):3449-3457. doi: 10.1200/JCO.2016.71.7629. Epub 2017 Aug 30.

PMID:
28854067
14.

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.

Kuiper JL, Hashemi SM, Thunnissen E, Snijders PJ, Grünberg K, Bloemena E, Sie D, Postmus PE, Heideman DA, Smit EF.

Br J Cancer. 2016 Dec 6;115(12):1504-1512. doi: 10.1038/bjc.2016.372. Epub 2016 Nov 22.

15.

Risk of spontaneous pneumothorax due to air travel and diving in patients with Birt-Hogg-Dubé syndrome.

Johannesma PC, van de Beek I, van der Wel JW, Paul MA, Houweling AC, Jonker MA, van Waesberghe JH, Reinhard R, Starink TM, van Moorselaar RJ, Menko FH, Postmus PE.

Springerplus. 2016 Sep 7;5(1):1506. doi: 10.1186/s40064-016-3009-4. eCollection 2016.

16.

Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis?

Johannesma PC, Houweling AC, Menko FH, van de Beek I, Reinhard R, Gille JJ, van Waesberghe JT, Thunnissen E, Starink TM, Postmus PE, van Moorselaar RJ.

Fam Cancer. 2016 Apr;15(2):297-300. doi: 10.1007/s10689-015-9853-5.

17.

Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study.

Hendriks LE, Derks JL, Postmus PE, Damhuis RA, Houben RM, Troost EG, Hochstenbag MM, Smit EF, Dingemans AM.

Eur J Cancer. 2015 Nov;51(17):2534-44. doi: 10.1016/j.ejca.2015.08.008. Epub 2015 Aug 28.

PMID:
26323530
18.

Close Surveillance with Long-Term Follow-up of Subjects with Preinvasive Endobronchial Lesions.

van Boerdonk RA, Smesseim I, Heideman DA, Coupé VM, Tio D, Grünberg K, Thunnissen E, Snijders PJ, Postmus PE, Smit EF, Daniels JM, Sutedja TG.

Am J Respir Crit Care Med. 2015 Dec 15;192(12):1483-9. doi: 10.1164/rccm.201504-0822OC.

PMID:
26275031
19.

Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?

Vincenten JP, Smit EF, Grünberg K, Postmus PE, Snijders PJ, Witte BI, Heideman DA, Thunnissen E.

Lung Cancer. 2015 Jul;89(1):19-26. doi: 10.1016/j.lungcan.2015.04.005. Epub 2015 Apr 20.

PMID:
25982011
20.

Long-term follow-up after first-line bronchoscopic therapy in patients with bronchial carcinoids.

Brokx HA, Paul MA, Postmus PE, Sutedja TG.

Thorax. 2015 May;70(5):468-72. doi: 10.1136/thoraxjnl-2014-206753. Epub 2015 Mar 16.

PMID:
25777586
21.

Detecting resistance in EGFR-mutated non-small-cell lung cancer after clonal selection through targeted therapy.

Kuiper JL, Bahce I, Voorhoeve C, Yaqub M, Heideman DA, Thunnissen E, Paul MA, Postmus PE, Hendrikse NH, Smit EF.

Per Med. 2015 Mar;12(2):63-66. doi: 10.2217/pme.14.64.

PMID:
29754538
22.

DNA hypermethylation analysis in sputum for the diagnosis of lung cancer: training validation set approach.

Hubers AJ, Heideman DA, Burgers SA, Herder GJ, Sterk PJ, Rhodius RJ, Smit HJ, Krouwels F, Welling A, Witte BI, Duin S, Koning R, Comans EF, Steenbergen RD, Postmus PE, Meijer GA, Snijders PJ, Smit EF, Thunnissen E.

Br J Cancer. 2015 Mar 17;112(6):1105-13. doi: 10.1038/bjc.2014.636.

23.

Pleural fluid is surrogate for time.

Postmus PE.

J Thorac Dis. 2014 Dec;6(12):E299-300. doi: 10.3978/j.issn.2072-1439.2014.11.24. No abstract available.

24.

Prevalence of Birt-Hogg-Dubé syndrome in patients with apparently primary spontaneous pneumothorax.

Johannesma PC, Reinhard R, Kon Y, Sriram JD, Smit HJ, van Moorselaar RJ, Menko FH, Postmus PE; Amsterdam BHD working group.

Eur Respir J. 2015 Apr;45(4):1191-4. doi: 10.1183/09031936.00196914. Epub 2014 Dec 23. No abstract available.

25.

The pathogenesis of pneumothorax in Birt-Hogg-Dubé syndrome: a hypothesis.

Johannesma PC, Houweling AC, van Waesberghe JH, van Moorselaar RJ, Starink TM, Menko FH, Postmus PE.

Respirology. 2014 Nov;19(8):1248-50. doi: 10.1111/resp.12405.

26.

In-flight pneumothorax: diagnosis may be missed because of symptom delay.

Postmus PE, Johannesma PC, Menko FH, Paul MA.

Am J Respir Crit Care Med. 2014 Sep 15;190(6):704-5. doi: 10.1164/rccm.201404-0698LE. No abstract available.

PMID:
25221882
27.

Retrospective evaluation of thromboembolic events in patients with non-small cell lung cancer treated with platinum-based chemotherapy.

Mellema WW, van der Hoek D, Postmus PE, Smit EF.

Lung Cancer. 2014 Oct;86(1):73-7. doi: 10.1016/j.lungcan.2014.07.017. Epub 2014 Aug 2.

PMID:
25129368
28.

Spontaneous pneumothorax as indicator for Birt-Hogg-Dubé syndrome in paediatric patients.

Johannesma PC, van den Borne BE, Gille JJ, Nagelkerke AF, van Waesberghe JT, Paul MA, van Moorselaar RJ, Menko FH, Postmus PE.

BMC Pediatr. 2014 Jul 3;14:171. doi: 10.1186/1471-2431-14-171.

29.

Granular cell tumor of the oral cavity; a case series including a case of metachronous occurrence in the tongue and the lung.

van de Loo S, Thunnissen E, Postmus P, van der Waal I.

Med Oral Patol Oral Cir Bucal. 2015 Jan 1;20(1):e30-3.

30.

Facial fibrofolliculomas as indicator for renal cell cancer.

Johannesma PC, Starink TM, Van Moorselaar RJ, Postmus PE.

Jpn J Clin Oncol. 2014 Jun;44(6):609-10. doi: 10.1093/jjco/hyu036. No abstract available.

PMID:
24864271
31.

Bilateral renal tumour as indicator for birt-hogg-dubé syndrome.

Johannesma PC, van Moorselaar RJ, Horenblas S, van der Kolk LE, Thunnissen E, van Waesberghe JH, Menko FH, Postmus PE.

Case Rep Med. 2014;2014:618675. doi: 10.1155/2014/618675. Epub 2014 Mar 20.

32.

Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.

Kuiper JL, Heideman DA, Thunnissen E, Paul MA, van Wijk AW, Postmus PE, Smit EF.

Lung Cancer. 2014 Jul;85(1):19-24. doi: 10.1016/j.lungcan.2014.03.016. Epub 2014 Mar 23.

PMID:
24768581
33.

Benefit of a second opinion for lung cancer: no metastasis to the kidney but a synchronous primary renal neoplasm.

Ter Avest MJ, Schook RM, Koudstaal LG, Grünberg K, Paul MA, Smit EF, Postmus PE.

Case Rep Oncol. 2014 Feb 19;7(1):122-5. doi: 10.1159/000359996. eCollection 2014 Jan.

34.

High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib.

Kuiper JL, Heideman DA, Thunnissen E, van Wijk AW, Postmus PE, Smit EF.

Eur J Cancer. 2014 May;50(7):1399-401. doi: 10.1016/j.ejca.2014.02.005. Epub 2014 Feb 28. No abstract available.

PMID:
24582911
35.

Why do patients and caregivers seek answers from the Internet and online lung specialists? A qualitative study.

Schook RM, Linssen C, Schramel FM, Festen J, Lammers E, Smit EF, Postmus PE, Westerman MJ.

J Med Internet Res. 2014 Feb 4;16(2):e37. doi: 10.2196/jmir.2842.

36.

How reliable are clinical criteria in distinguishing between Birt-Hogg-Dubé syndrome and smoking as a cause for pneumothorax?

Johannesma PC, Thunnissen E, Postmus PE.

Histopathology. 2014 Jun;64(7):1045-6. doi: 10.1111/his.12362. Epub 2014 Mar 8. No abstract available.

PMID:
24383416
37.

Benefit of a second opinion: From metastatic disease to resectable lung cancer with sarcoid-like reaction.

Schook RM, Koudstaal L, Comans EF, Postmus PE, Grünberg K, Paul MA, Smit EF, Sutedja TG.

Respir Med Case Rep. 2014 Aug 12;13:26-7. doi: 10.1016/j.rmcr.2014.07.002. eCollection 2014.

38.

DNA copy number aberrations in endobronchial lesions: a validated predictor for cancer.

van Boerdonk RA, Daniels JM, Snijders PJ, Grünberg K, Thunnissen E, van de Wiel MA, Ylstra B, Postmus PE, Meijer CJ, Meijer GA, Smit EF, Sutedja TG, Heideman DA.

Thorax. 2014 May;69(5):451-7. doi: 10.1136/thoraxjnl-2013-203821. Epub 2013 Nov 13.

PMID:
24227199
39.

Lung cysts as indicator for Birt-Hogg-Dubé syndrome.

Johannesma PC, Thunnissen E, Postmus PE.

Lung. 2014 Feb;192(1):215-6. doi: 10.1007/s00408-013-9522-0. Epub 2013 Oct 22.

PMID:
24146214
40.

Right ventricular diastolic impairment in patients with pulmonary arterial hypertension.

Rain S, Handoko ML, Trip P, Gan CT, Westerhof N, Stienen GJ, Paulus WJ, Ottenheijm CA, Marcus JT, Dorfmüller P, Guignabert C, Humbert M, Macdonald P, Dos Remedios C, Postmus PE, Saripalli C, Hidalgo CG, Granzier HL, Vonk-Noordegraaf A, van der Velden J, de Man FS.

Circulation. 2013 Oct 29;128(18):2016-25, 1-10. doi: 10.1161/CIRCULATIONAHA.113.001873. Epub 2013 Sep 20.

PMID:
24056688
41.

EGFR mutation analysis in sputum of lung cancer patients: a multitechnique study.

Hubers AJ, Heideman DA, Yatabe Y, Wood MD, Tull J, Tarón M, Molina MA, Mayo C, Bertran-Alamillo J, Herder GJ, Koning R, Sie D, Ylstra B, Meijer GA, Snijders PJ, Witte BI, Postmus PE, Smit EF, Thunnissen E.

Lung Cancer. 2013 Oct;82(1):38-43. doi: 10.1016/j.lungcan.2013.07.011. Epub 2013 Aug 5.

PMID:
23927883
42.

Website visitors asking questions online to lung cancer specialists: what do they want to know?

Schook RM, Linssen C, Festen J, Schramel FM, Lammers E, Zaanen P, Postmus PE.

Interact J Med Res. 2013 Aug 6;2(2):e15. doi: 10.2196/ijmr.1749.

43.

Can quantifying free-circulating DNA in plasma be used to identify subjects with high-grade pre-invasive endobronchial lesions?

VAN Boerdonk RA, Brokx HA, Lee P, Kooi C, Postmus PE, Snijders PJ, Grünberg K, Thunnissen E, Sutedja TG, Daniels JM, Heideman DA.

Oncol Lett. 2013 May;5(5):1591-1594. Epub 2013 Mar 19.

44.

Benefit of a second opinion: intrapulmonary metastases or multiple primary tumors?

ter Avest MJ, Schook RM, Postmus PE, Grünberg K, Ylstra B, Paul MA.

J Thorac Oncol. 2013 Jun;8(6):e54-6. doi: 10.1097/JTO.0b013e31828c28c6. No abstract available.

45.

The stage classification of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Detterbeck FC, Postmus PE, Tanoue LT.

Chest. 2013 May;143(5 Suppl):e191S-e210S. doi: 10.1378/chest.12-2354. Review.

PMID:
23649438
46.

Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [¹¹C]docetaxel and positron emission tomography.

van der Veldt AA, Lubberink M, Mathijssen RH, Loos WJ, Herder GJ, Greuter HN, Comans EF, Rutten HB, Eriksson J, Windhorst AD, Hendrikse NH, Postmus PE, Smit EF, Lammertsma AA.

Clin Cancer Res. 2013 Aug 1;19(15):4163-73. doi: 10.1158/1078-0432.CCR-12-3779. Epub 2013 Apr 25.

47.

Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus.

Blaauwgeers JL, Kappers I, Klomp HM, Belderbos JS, Dijksman LM, Smit EF, Postmus PE, Paul MA, Oosterhuis JW, Hartemink KJ, Vos CG, Burgers JA, Dahele M, Phernambucq EC, Witte BI, Thunnissen E.

Virchows Arch. 2013 May;462(5):547-56. doi: 10.1007/s00428-013-1404-6. Epub 2013 Apr 3.

PMID:
23549732
48.

Ventilator-associated pneumothorax: drainage is not always necessary.

Postmus PE.

Respiration. 2013;85(5):365-6. doi: 10.1159/000348371. Epub 2013 Mar 13. No abstract available.

49.

Exhaled molecular profiles in the assessment of cystic fibrosis and primary ciliary dyskinesia.

Paff T, van der Schee MP, Daniels JM, Pals G, Postmus PE, Sterk PJ, Haarman EG.

J Cyst Fibros. 2013 Sep;12(5):454-60. doi: 10.1016/j.jcf.2012.12.010. Epub 2013 Jan 27.

50.

A de novo FLCN mutation in a patient with spontaneous pneumothorax and renal cancer; a clinical and molecular evaluation.

Menko FH, Johannesma PC, van Moorselaar RJ, Reinhard R, van Waesberghe JH, Thunnissen E, Houweling AC, Leter EM, Waisfisz Q, van Doorn MB, Starink TM, Postmus PE, Coull BJ, van Steensel MA, Gille JJ.

Fam Cancer. 2013 Sep;12(3):373-9. doi: 10.1007/s10689-012-9593-8.

PMID:
23264078

Supplemental Content

Loading ...
Support Center